Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Theradiag SA Receives 3rd CE Mark Approval for New Anti-CCP In-Vitro Diagnostic Kit in Rheumatoid Arthritis


Tuesday, 23 Apr 2013 02:00am EDT 

Theradiag SA announced that it has obtained a CE mark for its anti-CCP in vitro diagnostic (IVD) kit in rheumatoid arthritis. 

Related Company News

Company Quote

3.95
-0.05 -1.25%
24 Dec 2014